Skip to main content


Table 2 Attitudes toward clinical trials and study participation

From: Clinical features of Parkinson’s disease patients are associated with therapeutic misconception and willingness to participate in clinical trials

Statements Agreement “cannot say” Disagreement
n % n % n %
Persons diagnosed with PD should be asked to participate in CTs 559 83 81 12 32 5
If patients refuse to participate in CTs, new treatments will not become available 417 63 140 21 108 16
Research results should be discussed with research participants 634 95 17 3 13 2
I think it is important that all clinical trials’ results be published and health-care professionals gain access to them 620 93 29 4 19 3
I would like to receive as much information as possible about the trial and the new drug before I make a decision about participation in a CT 561 83 57 9 54 8
New PD medications are usually studied in comparative trials (an old drug is compared to a new substance or a placebo); I would like to participate in this kind of CT 336 50 177 26 157 23
I would participate in clinical trials because it would enable me to help other patients with Parkinson’s disease 567 86 64 10 32 5
I would participate in a CT in which there is a possibility of receiving a placebo (placebos do not contain any active ingredient) 274 42 145 22 238 36
I would participate in a CT if it involved a significant risk of severe adverse effects (adverse effects that could lead to prolongation of hospitalization or cause permanent disability) 34 10 100 15 492 75
  1. The agreement and disagreement categories were formed by combining the “agree” and “strongly agree” responses and the “disagree” and “strongly disagree” responses, respectively. CT clinical trial, PD Parkinson’s disease